Filing summary: Cara Therapeutics, Inc. — FY 2014 Form 10-K
Entity mismatch: The request identifies Tvardi Therapeutics, Inc., but the supplied filing is for Cara Therapeutics, Inc. The filing covers the fiscal year ended December 31, 2014; it also reports fourth-quarter results. This summary reflects the supplied filing, not Tvardi.
Business context and reporting period
Cara was a clinical-stage biopharmaceutical company developing peripheral-acting therapies for pain and pruritus. Its lead candidate, intravenous CR845, was in Phase 3 planning for acute postoperative pain and in a Phase 2 proof-of-concept study for uremic pruritus. Oral CR845 was approaching Phase 2; CR701 remained preclinical. Cara had no products approved for sale and no product-sale revenue. Its revenue primarily came from licensing, collaboration services and clinical compound sales.
Financial performance and liquidity
| Metric | FY 2014 | FY 2013 |
|---|---|---|
| Total revenue | $3.2 million | $12.0 million |
| Research and development expense | $15.1 million | $8.7 million |
| General and administrative expense | $6.2 million | $3.5 million |
| Operating loss | $18.1 million | $0.2 million |
| Net loss | $17.7 million | $4.0 million |
| Net loss per share | $0.85 | $0.74 |
| Net cash used in operating activities | $17.6 million | Net cash provided: $2.8 million |
Revenue fell 73%, largely because 2013 included substantial recognition of the Maruishi upfront license fee; 2014 revenue included $2.2 million of collaborative revenue, $0.7 million of clinical compound revenue and $0.3 million of license and milestone revenue. R&D expense rose 73%, principally with CR845 manufacturing and new oral CR845, uremic-pruritus and human-abuse-liability studies. G&A rose 76%, reflecting public-company costs, payroll, insurance and stock-based compensation. Profitability and operating margins are not meaningful for this pre-commercial, loss-making company.
At year-end, cash and cash equivalents were $52.7 million, up from $12.4 million; total assets were $55.9 million, total liabilities $4.3 million, and stockholders’ equity $51.7 million. Restricted cash of $0.7 million secured the lease. The company had no outstanding convertible preferred stock or debt at year-end; prior convertible notes and the Connecticut Innovations term loan had been converted or repaid. Operating lease commitments totaled $2.5 million through 2017. The IPO generated approximately $56.3 million in net proceeds as reported in the filing. FY 2014 financing cash flow was $58.0 million.
Management estimated that year-end cash would fund operations for at least 15 months, excluding potential collaboration milestones, but stated that additional capital was needed to meet all development objectives, including the planned Phase 3 program. No dividends were planned.
Material changes and notable items
- Compared with 2013, the company moved from modest operating loss to an $18.1 million operating loss as revenue normalized and development spending increased. The prior-year net loss was also affected by $3.7 million of non-cash interest expense related to convertible notes; those notes were converted or repaid in 2013.
- The January 2014 IPO and automatic conversion of all preferred shares materially increased common shares outstanding and moved the balance sheet from a stockholders’ deficit to positive equity.
- Cash from operations shifted from a $2.8 million inflow in 2013 to a $17.6 million outflow in 2014. The filing attributes the 2013 inflow partly to increased deferred revenue from Maruishi.
- Quarterly 2014 revenue was $0.2 million, $1.0 million, $1.1 million and $0.9 million, respectively; quarterly net losses available to common stockholders were $3.4 million, $3.6 million, $6.5 million and $4.2 million.
- The audited financial statements received an unqualified opinion from Ernst & Young. Management concluded disclosure controls and internal control over financial reporting were effective as of year-end.
Outlook, commentary and principal risks
Management planned an FDA End-of-Phase-2 meeting in Q2 2015, with the first I.V. CR845 Phase 3 trial expected to start in Q2 2015 and two additional trials in the second half of 2015. Oral CR845 Phase 2 was also planned for Q2 2015. Top-line efficacy results from the uremic-pruritus study were expected in Q2 2015. These are forward-looking plans, not reported outcomes.
Management highlighted positive Phase 2 pain findings and favorable tolerability to date. In a completed human abuse-liability trial, I.V. CR845 showed significantly lower drug-liking scores than pentazocine; however, non-scheduled or Schedule V status was only a potential outcome, not a regulatory determination. Reported or monitored safety issues included transient facial tingling, dizziness, fatigue, somnolence, increased urine output and possible sodium elevation/dehydration effects. The filing cautions that later trials may reveal new safety issues or fail to confirm earlier efficacy.
Key risks include dependence on successful Phase 3 trials and regulatory approval; the need for additional financing; uncertain commercial adoption, reimbursement and pricing; possible DEA scheduling or other distribution restrictions; reliance on third-party manufacturers, CROs and collaborators; competition from established and generic pain therapies; and patent, product-liability and regulatory-compliance risks. Maruishi could terminate its agreement at will, and future milestone and royalty receipts were uncertain. No material legal proceedings were reported.
Important facts for investors to verify
- Confirm the issuer identity: the supplied document is Cara Therapeutics’ 2014 Form 10-K, not a Tvardi Therapeutics filing.
- Check subsequent filings for actual Phase 3 start dates, trial designs, enrollment, results and FDA feedback against the plans stated here.
- Assess cash burn, financing needs and runway against the stated 15-month estimate and the costs of the planned clinical program.
- Verify the full terms, remaining milestones and status of the Maruishi and CKD collaborations, including any later payments or changes.
- Track later safety findings, regulatory decisions on DEA scheduling, and commercial coverage, reimbursement and manufacturing readiness.